As if biomarker discovery isn't hard enough: The consequences of poorly characterized reagents

Clinical Chemistry

Volumn 60, Issue 2, 2014, Pages 290-291

  Rodland, Karin D ^a  

^a PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; REAGENT; DIAGNOSTIC KIT;

CANCER STAGING; CANCER SURVIVAL; EDITORIAL; ELISA KIT; FALSE POSITIVE RESULT; HUMAN; OVARY CANCER; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; DIAGNOSTIC KIT; EARLY DIAGNOSIS; HIGH THROUGHPUT SCREENING; NEOPLASMS; PATHOLOGY; PROCEDURES; STANDARDS;

BIOLOGICAL MARKERS; EARLY DIAGNOSIS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; NEOPLASM STAGING; NEOPLASMS; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY;

EID: 84893435291     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2013.216382     Document Type: Editorial

References (14)

1. Fuzery AK, Levin J, Chan MM, Chan DW. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics 2013;10:13.
2. Rooth C. Ovarian cancer: risk factors, treatment and management. Br J Nurs 2013;22:S23-30.
3. Skates SJ. Ovarian cancer screening: development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials. Int J Gynecol Cancer 2012;22 Suppl 1:S24-6.
4. Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, et al. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Research 2011;4:375-83.
5. Diamandis EP. The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem? BMC Med 2012;10:87.
6. Hanash SM. Why have protein biomarkers not reached the clinic? Genome Med 2011;3:66.
7. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-61.
8. Feng Z, Kagan J, Pepe M, Thornquist M, Ann Rinaudo J, Dahlgren J, et al. The Early Detection Research Network's specimen reference sets: paving the way for rapid evaluation of potential biomarkers. Clin Chem 2013;59:68-74.
9. Prassas I, Brinc D, Farkona S, Leung F, Dimitromanolakis A, Chrystoja CC, et al. False biomarker discovery due to reactivity of a commercial ELISA for CUZD1 with cancer antigen CA125. Clin Chem 2013;60:381-8.
10. Prassas I, Chrystoja CC, Makawita S, Diamandis EP. Bioinformatic identification of proteins with tissue-specific expression for biomarker discovery. BMC Med 2012;10:39.
11. Karam AK, Karlan BY. Ovarian cancer: the duplicity of CA125 measurement. Nat Rev Clin Oncol 2010;7:335-9.
12. Gutierrez OM, Sun CC, Chen W, Babitt JL, Lin HY. Statement of concern about a commercial assay used to measure soluble hemojuvelin in humans. Am J Bephrol 2012;36:332-3; author reply 333.
13. Kuhn E, Whiteaker JR, Mani DR, Jackson AM, Zhao L, Pope ME, et al. Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma. Mol Cell Proteomics 2012;11:M111.013854.
14. Shi T, Fillmore TL, Sun X, Zhao R, Schepmoes AA, Hossain M, et al. Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum. Proc Natl Acad Sci U S A 2012;109:15395-400.